Comparison of the measured values of quantitative SARS-CoV-2 spike antibody assays

Müller, Lars Peter; Kannenberg, Judith; Biemann, Ronald; Hönemann, Mario; Ackermann, Grit; Jassoy, Christian

doi:10.1016/j.jcv.2022.105269

Cited by 18 publications

(23 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antibody titers were decreased in participants aged 50 to 59 years and 60 to 64 years. The decrease in antibody titer in older age groups were consistent with the previous studies ( Anastassopoulou et al, 2022 ; Grupel et al, 2021 ; Müller et al, 2022 ).…”

Section: Discussionsupporting

confidence: 92%

Time of Day of Vaccination Does Not Associate With SARS–CoV–2 Antibody Titer Following First Dose of mRNA COVID–19 Vaccine

et al. 2022

View full text Add to dashboard Cite

The immune system exhibits circadian rhythms, and its response to viral infection is influenced by the circadian clock system. Previous studies have reported associations between the time of day of vaccination against COVID-19 and production of anti-SARS-CoV-2 antibody titer. We examined the effect of vaccination time of day on anti-SARS-CoV-2 antibody titer after the first dose of vaccination with the mRNA-1273 (Moderna) COVID-19 vaccine in an adult population. A total of 332 Japanese adults participated in the present study. All participants were not infected with SARS-CoV-2 and had already received the first dose of mRNA-1273 2 to 4 weeks prior to participating in the study. The participants were asked to provide basic demographic characteristics (age, sex, medical history, allergy, medication, and mean sleep duration), the number of days after the first dose of vaccination, and the time of day of vaccination. Blood was collected from the participants, and SARS-CoV-2 antibody titers were measured. Ordinary least square regression was used for assessing the relationship between basic demographic characteristics, number of days after vaccination, time of day of vaccination, and the log10-transformed normalized antibody titer. The least square mean of antibody titers was not associated with the vaccination time and sleep durations. The least square means of antibody titers was associated with age; the antibody titers decreased in people aged 50 to 59 years and 60 to 64 years. The present findings demonstrate that the vaccination time with mRNA-1273 was not associated with the SARS-CoV-2 antibody titer in an adult population, suggesting that these results do not support restricting vaccination to a particular time of day. The present findings may be useful in optimizing SARS-CoV-2 vaccination strategies.

show abstract

Section: Discussionsupporting

confidence: 92%

Time of Day of Vaccination Does Not Associate With SARS–CoV–2 Antibody Titer Following First Dose of mRNA COVID–19 Vaccine

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Despite the obvious progress in the standardization of methods for determining the level of antibodies to SARSCoV-2 in the blood of people who have had an infection (using the international standard BAU/mL recommended by WHO) a comparison of the results obtained using various commercial tests reveals their significant discrepancy in quantitative terms [ 29 , 39 , 40 , 43 , 44 ].…”

Section: Discussionmentioning

confidence: 99%

“…The few literature data on this subject are contradictory. In particular higher values in BAU/mL have been reported for the Siemens and EuroImmun assays compared to the Abbott assay [ 40 , 44 ]. One study reported that Roche assay showed significantly higher BAU/mL values for anti-SARS-CoV-2 IgG than Abbott, Siemens and EuroImmun assays [40] however another study found opposite results [43] .…”

Section: Discussionmentioning

confidence: 99%

Nonlinear interdependence of the results of measuring anti-SARS-CoV-2 IgG levels using Abbott and Euroimmun test systems

Ivanov

Kryshen

Семенова

2023

Journal of Clinical Virology

View full text Add to dashboard Cite

“…All assays were performed according to the manufacturer's instructions. Binding antibodies were measured as units per mL (U/mL), and SARS-CoV-2 binding antibody units per mL (BAU/mL) were calculated according to the WHO international standard for anti-SARS-CoV-2 immunoglobulin using conversion factors (Roche 1.028, Abbott 0.142) (11)(12)(13). The cut-off value of 0.8 U/mL was applied for the Roche total antibody assay, while 50 AU/ mL was provided as a cut-off for the Abbott IgG binding antibody assay.…”

Section: Sars-cov-2 Binding Antibody Detectionmentioning

confidence: 99%

Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study

et al. 2023

View full text Add to dashboard Cite

IntroductionThe differential immune responses after two additional BNT162b2 (BNT) booster doses between ChAdOx1 nCoV-10 (ChAd)-primed and BNT-primed groups have not been elucidated. The aim of this study was to compare vaccine-induced humoral and cellular immune responses and evaluate breakthrough infection between the two vaccination strategies.MethodsIn 221 healthy subjects (111 in the ChAd group), longitudinal immune responses were monitored at 3, 4, and 6 months after the 2nd dose and 1, 3, and 6 months after the 3rd dose. Humoral immunity was measured by two fully automated chemiluminescent immunoassays (Elecsys and Abbott) and a surrogate virus neutralization test (sVNT). Cellular immunity was assessed by two interferon-γ (IFN-γ) release assays (QuantiFERON SARS-CoV-2 and Covi-FERON).ResultsAfter the 2nd dose of BNT vaccination, total antibody levels were higher in the ChAd group, but IgG antibody and sVNT results were higher in the BNT group. Following the 3rd dose vaccination, binding antibody titers were significantly elevated in both groups (ChAD-BNT; 15.4 to 17.8-fold, BNT-BNT; 22.2 to 24.6-fold), and the neutralizing capacity was increased by 1.3-fold in both cohorts. The ChAd-BNT group had lower omicron neutralization positivity than the BNT-BNT group (P = 0.001) at 6 months after the 3rd dose. Cellular responses to the spike antigen also showed 1.7 to 3.0-fold increases after the 3rd dose, which gradually declined to the levels equivalent to before the 3rd vaccination. The ChAd cohort tended to have higher IFN-γ level than the BNT cohort for 3-6 months after the 2nd and 3rd doses. The frequency of breakthrough infection was higher in the ChAd group (44.8%) than in the BNT group (28.1%) (P = 0.0219). Breakthrough infection induced increased humoral responses in both groups, and increase of cellular response was significant in the ChAd group.DiscussionOur study showed differential humoral and cellular immune responses between ChAd-BNT-BNT heterologous and BNT-BNT-BNT homologous vaccination cohorts. The occurrence of low antibody levels in the ChAd-primed cohort in the humoral immune response may be associated with an increased incidence of breakthrough infections. Further studies are needed on the benefits of enhanced cellular immunity in ChAd-primed cohorts.

show abstract

Comparison of the measured values of quantitative SARS-CoV-2 spike antibody assays

Cited by 18 publications

References 14 publications

Time of Day of Vaccination Does Not Associate With SARS–CoV–2 Antibody Titer Following First Dose of mRNA COVID–19 Vaccine

Time of Day of Vaccination Does Not Associate With SARS–CoV–2 Antibody Titer Following First Dose of mRNA COVID–19 Vaccine

Nonlinear interdependence of the results of measuring anti-SARS-CoV-2 IgG levels using Abbott and Euroimmun test systems

Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study

Contact Info

Product

Resources

About